According to Bloomberg sources, French drugmaker Sanofi is considering the disposal of its bio-surgery, renal and Merial animal health units as part of a strategic business review.
No final decision has been made and Sanofi may choose to keep the assets, sources said. An update is expected at an investor meeting in November.
Sanofi's bio-surgery business, obtained through a 2011 purchase of Genzyme Corp., has annual sales of about $223M. Sanofi acquired Merck’s 50% stake in Merial animal health in 2009. Sales are about $2.6 billion.
In July, Sanofi announced that it will adopt a simplified structure centered around five global business units. The reorg came under the control of newly hired CEO, Olivier Brandicourt, who took the wheel in April. Brandicourt has said that he will present a five-year strategic growth plan in November.
Read the Bloomberg release